Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma
Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma
复制标题
血清高尔基体蛋白 73 是肝细胞癌的预后而非诊断标志物
DOI：
10.3892/ol.2017.6938
复制
发表时间：
2017-11-01
期刊：
影响因子：
2.9
通讯作者：
Wu, Xiang-Yuan
中科院分区：
文献类型：
--
作者：
Dong, Min;Chen, Zhan-Hong;Wu, Xiang-Yuan
血清Golgi蛋白73（sGP 73）是肝细胞癌（HCC）的候选诊断生物标志物。然而，目前关于其诊断价值的证据是相互矛盾的，主要是由于先前研究的样本量小，并且其在HCC中的预后作用也仍然不清楚。在本研究中，使用ELISA评估了462名HCC患者、186名肝硬化患者和83名健康对照者的sGP 73水平，并且确定了HCC患者的中位sGP 73水平显著更高。（18.7 ng/ml）和肝硬化（18.5 ng/ml）患者比健康对照组（0 ng/ml;均P < 0.001）;然而，HCC组和肝硬化组之间的水平没有显著差异（P=0.632）。sGP 73诊断HCC的敏感性和特异性分别为27.79%和77.96%，显著低于甲胎蛋白（57.36%和90.96%，P < 0.001）。在HCC组中，高水平的sGP 73与侵袭性临床病理特征相关，并独立预测较差的总生存（OS）时间（P < 0.001）。此外，在可切除的HCC患者中，与低水平sGP 73相比，高水平sGP 73与无病生存期（P < 0.001）和OS（P=0.039）时间显著降低相关。这项研究表明，sGP 73是不适合作为早期检测肝癌的诊断标志物，但它是一个独立的负预后标志物，提供了一个新的危险分层因素和潜在的治疗肝癌的分子靶点。
Serum Golgi protein 73 (sGP73) is a candidate diagnostic biomarker for hepatocellular carcinoma (HCC). However, current evidence of its diagnostic value is conflicting, primarily due to the small sample sizes of previous studies, and its prognostic role in HCC also remains unclear. In the present study, sGP73 levels in 462 patients with HCC, 186 patients with liver cirrhosis, and 83 healthy controls were evaluated using ELISA, and it was identified that the median sGP73 levels were significantly higher in the HCC (18.7 ng/ml) and liver cirrhosis (18.5 ng/ml) patients than in the healthy controls (0 ng/ml; both P < 0.001); however, the levels did not significantly differ between the HCC and liver cirrhosis groups (P=0.632). sGP73 had an inferior sensitivity and specificity for HCC diagnosis (27.79 and 77.96%, respectively) compared with a-fetoprotein (57.36 and 90.96%, respectively; P < 0.001). In the HCC group, a high level of sGP73 was associated with aggressive clinicopathological features and independently predicted poor overall survival (OS) time (P < 0.001). Additionally, in patients with resectable HCC, a high level of sGP73 was associated with significantly decreased disease-free survival (P < 0.001) and OS (P=0.039) times compared with a low level of sGP73. This study demonstrated that sGP73 is unsuitable as a diagnostic marker for the early detection of HCC; however, it is an independent negative prognostic marker, providing a novel risk stratification factor and a potential therapeutic molecular target for HCC.